gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · EDITHealthcareBiotechnology

Editas Medicine, Inc. Common Stock (EDIT)

$2.72+4.62%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.72▼ 2.16% in range
Nov 4, 2025Low $1.67 · High $3.75Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Editas Medicine closed at $2.72 on Nov 4, up 4.62%, 27.5% below its 52-week closing high. Volume of 2.4M shares was 1.00× its 20-day average (close to normal).

Split-adjusted performance: -0.4% over one month, -14.3% over six months, -11.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $11.89M, up 232.3% from a year earlier, with a net margin of -153.3%.

Short interest was 38.2M shares at the Oct 15 settlement, up 2.9% from the prior report (25.7% of float, 14.3 days to cover).

Market cap$417.7M153.6M shares
Revenue · quarter$11.9M+232.3% YoY
Diluted EPS$-0.15—
P/E · TTM—P/S 8.9×
Net margin-153.3%Gross 100.0%
Dividend yieldNone
52-week range1.67 – 3.75−27.5% from high
Volume2.4M1.00× 20-day avg
Volatility · 60d81.5%Annualised
Short % of float25.7%14.3 days to cover
Net cash$155.9MCash $211.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.8%1M −0.4%3M −6.2%6M −14.3%YTD +32.7%1Y −11.1%3Y −57.0%5Y −92.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum56
Revenue growth85
Net margin57
Value (low P/E)—
Size62

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short38.2M+2.9% vs prior
Days to cover14.3Settled Oct 15
% of float25.7%
Short vol. 10d55.3%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
EDITEditas Medicine$2.72+4.62%−14.3%+232.3%−153.3%—$417.7M
ALLOAllogene Therapeutics$1.19+6.25%−48.5%—−919.8%—$411.1MCompare
TECXTectonic Therapeutic$20.30+6.95%−30.0%———$396.9MCompare
ZURAZura Bio Limited$4.02+0.75%−17.8%———$387.2MCompare
CCCCC4 Therapeutics$3.12−2.80%+6.5%+2.8%−355.9%—$383.8MCompare
SRZNSurrozen$31.65+5.08%−7.3%+408.6%640.8%—$372.0MCompare
FENCFennec Pharmaceuticals$10.35−3.27%+44.2%+85.2%11.0%—$362.9MCompare
EIKNEikon Therapeutics$6.39+15.14%−35.9%———$346.1MCompare
RGNXREGENXBIO$7.71+1.05%−24.6%+405.7%21.0%—$509.0MCompare

News about Editas Medicine

All news →
EDIT Set to Begin First-in-Human Study in HypercholesterolemiaZacks Investment Research · Oct 9, 2026▲ PositiveEditas Medicine Appoints Dan Ory, M.D., as Chief Medical OfficerGlobeNewswire Inc. · Sep 8, 2026▲ PositiveLyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal DiseasesGlobeNewswire Inc. · Jul 14, 2026NeutralCRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?The Motley Fool · May 31, 2026NeutralEditas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business UpdatesGlobeNewswire Inc. · Mar 9, 2026▲ Positive

Quick answers

What does Editas Medicine do?
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities.
What is EDIT's market cap?
$417.74M, based on the Nov 4 close of $2.72.
Does Editas Medicine pay a dividend?
No regular cash dividend has been paid in the last year.
How much of EDIT is sold short?
38.2M shares, 25.7% of float, as of Oct 15, 2026.
What sector is EDIT in?
Healthcare, in the Biotechnology industry.

About Editas Medicine

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

HQ: Cambridge, MA87 employeesListed Feb 3, 2016editasmedicine.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology